Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
BioSpace6h
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
SHINE8hOpinion
Breakthroughs in Alzheimer's diagnosis and treatment portend multibillion-dollar industry
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Companies warn investors that DOGE’s federal cuts might hurt business
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
Medscape13h
Analysis Takes a Deep Dive Into Robust Response to Delgocitinib for Chronic Hand Eczema
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
Xavier sends Tom Lilly into retirement as a champion
For 40 seasons, Tom Lilly has built a legacy on the sidelines. In his final game as head coach, his Xavier Saints made sure he went out on top. Behind a histori ...